ERGIC1 and prostate carcinoma: In addition, although ERGIC1 and TMED3 were highly expressed in both ERG negative and positive prostate cancers, their mRNA expression levels positively correlated with ERG expression levels in ERG positive samples (P = 0.002 and P = 0.007 respectively) (Figure 4D).